Metabolic regulation of the anti-tumor CD8+ T cell response to PD-1 by asparagine
天冬酰胺对抗肿瘤 CD8 T 细胞对 PD-1 反应的代谢调节
基本信息
- 批准号:10672044
- 负责人:
- 金额:$ 4.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdoptive TransferAsparagineAspartateAspartate-Ammonia LigaseBiological Response ModifiersBlocking AntibodiesCD8-Positive T-LymphocytesCRISPR screenCRISPR/Cas technologyCancer PatientCarbonCell physiologyCellsCellular ImmunologyChronicClinicalCoculture TechniquesCombined Modality TherapyCytotoxic T-LymphocytesDevelopmentDisease remissionDissociationEnzymesGenesGlutamineGoalsImmune EvasionImmune ToleranceImmune systemImmunityImmunologic ReceptorsImmunologicsImpairmentIn VitroInfusion proceduresInterventionIsotope LabelingKnowledgeLabelLigandsLinkLymphocyteMaintenanceMediatingMetabolicMetabolic PathwayMetabolismMonoclonal AntibodiesMusNitrogenNutrientPathway interactionsPatientsPeripheralPlayProliferatingPropertyProtein BiosynthesisProteinsRegulationResearchResistanceResistance developmentRoleSupplementationSystemT cell responseT-Cell ActivationT-LymphocyteTechniquesTestingTherapeuticTranslatingTumor ImmunityValidationanti-PD-1anti-PD1 therapyasparaginasecancer clinical trialcancer typecombinatorialcytotoxicexhaustexhaustionexperimental studyextracellularfunctional genomicsimmune activationimmune checkpointimmune checkpoint blockadeimmunopathologyimprovedin vivoloss of functionneoplastic cellnovelnovel strategiespathogenpatient subsetspharmacologicprogenitorprogrammed cell death ligand 1programmed cell death protein 1responsestemsuccesssynergismtumortumor growthtumor microenvironmentuptake
项目摘要
Abstract
The T cell co-inhibitory checkpoint programmed cell death 1 (PD-1) plays a critical role in the maintenance of
peripheral immunological tolerance. However the PD-1 pathway can be co-opted by chronic pathogens and
tumor cells to promote immune evasion. Immune checkpoint blockade (ICB) using antibodies that block the PD-
1/PD-L1 ligand interactions have demonstrated remarkable success in cancer clinical trials. Despite inducing
durable responses in a subset of patients, most patients do not develop stable remission after therapy. Therefore,
it is critical to understand the immunological and cellular features associated with response and resistance to
ICB. Metabolic remodeling is intrinsically linked to the development, differentiation and activation of immune
cells, including anti-tumor T cells. Yet, little is known about the metabolic vulnerabilities of anti-tumor T cells,
including metabolic pathways that govern the reinvigoration of exhausted anti-tumor T cells during ICB therapy.
Our preliminary studies identified asparagine synthetase (Asns) as a novel metabolic regulator of the anti-
tumor CD8+ T cell response to anti-PD-1 therapy and provided evidence for a central role for asparagine
metabolism in regulating the efficacy of anti-PD-1 treatment in CD8+ T cell-mediated control of tumors. We will
test this hypothesis in two aims: 1) Define the metabolic pathway(s) regulated by asparagine metabolism in anti-
tumor CD8+ T cells and 2) Determine the role of asparagine metabolism in regulating CD8+ T cell exhaustion in-
vivo during PD-1 blockade. In Aim 1 we will systematically determine the metabolic mechanism(s) by which
asparagine regulates CD8+ T cells by comparing wild-type and CRISPR/Cas9-edited Asns-/- anti-tumor CD8+ T
cells. The fate(s) and contribution(s) of asparagine to distinct metabolic pathways, protein synthesis, and cytolytic
T cell activity will be assessed using isotopically labeled forms of asparagine, aspartate and glutamine in a novel
co-culture system with T cells and tumor cells. Aim 2 will comprehensively interrogate the roles of asparagine
metabolism, including asparagine synthesis and uptake, by leveraging functional genomic perturbation
approaches to target asparagine synthetase and the asparagine transporter SLC15A in exhausted CD8+ T cells
during anti-PD-1 treatment in tumor bearing-mice. Combinatorial approaches in which asparagine is
supplemented or pharmacologically depleted will reveal how modulation of this pathway regulates anti-tumor T
cell function and synergizes with ICB.
Our research is conceptually novel and will address an important gap in our understanding of metabolic
circuits critical for the maintenance and functional responses of exhausted anti-tumor CD8+ T cells during anti-
PD-1 therapy. Since little is known about metabolic pathway usage and vulnerabilities of T cells within a nutrient
limited tumor microenvironment, the identification and successful validation of asparagine metabolism as a
central metabolic node that regulates anti-PD-1 efficacy may ultimately enable novel clinical strategies to improve
the clinical response to ICB therapy by providing metabolic support to T cells.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Georgiev其他文献
Peter Georgiev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 4.44万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 4.44万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 4.44万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 4.44万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 4.44万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 4.44万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 4.44万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 4.44万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 4.44万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 4.44万 - 项目类别:














{{item.name}}会员




